InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,281.32
(
0.30%
)
Post# of 252301
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: DonShimoda post# 127344

Monday, 09/26/2011 11:19:28 AM

Monday, September 26, 2011 11:19:28 AM

Post# of 252301
It's worth noting that the 63% CCyR response for pona in 3rd-line patients is quite comparable to the 66% figure for Gleevec in 1st-line patients.

This drug really does look to be best in class. I'm guessing that for 1st-line patients a lower dose (30mg) will work fine, and so the practical side-effect profile could potentially improve even further.

Peter
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up